within Pharmacolibrary.Drugs.ATC.A;

model A10BK03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.78,
    Cl             = 10.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 0.07379999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015166666666666667,
    Tlag           = 120.0
  );

  annotation(Documentation(
    info ="<html><body><p>Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily for the management of type 2 diabetes mellitus. It lowers blood glucose by increasing renal glucose excretion. Empagliflozin is approved and widely used in clinical practice, including for reduction of cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model in healthy adult volunteers after oral administration; parameters apply to both male and female adults.</p><h4>References</h4><ol><li><p>Frampton, JE (2018). Empagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 78(10) 1037–1048. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0937-z&quot;>10.1007/s40265-018-0937-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29946963/&quot;>https://pubmed.ncbi.nlm.nih.gov/29946963</a></p></li><li><p>Griffin, M, et al., &amp; Testani, JM (2020). Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> 142(11) 1028–1039. DOI:<a href=&quot;https://doi.org/10.1161/CIRCULATIONAHA.120.045691&quot;>10.1161/CIRCULATIONAHA.120.045691</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32410463/&quot;>https://pubmed.ncbi.nlm.nih.gov/32410463</a></p></li><li><p>Chen, G, et al., &amp; Wang, J (2020). Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study. <i>Pharmacotherapy</i> 40(7) 623–631. DOI:<a href=&quot;https://doi.org/10.1002/phar.2432&quot;>10.1002/phar.2432</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32498113/&quot;>https://pubmed.ncbi.nlm.nih.gov/32498113</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BK03;
